B. Bray

发表

Oxidative radical cyclization to pyrroles under reducing conditions. Reductive desulfonylation of α-sulfonylpyrroles with tri-n-butyltin hydride

David A. Lustig, Y. Antonio, M. E. Cruz, 1994 .

Innovation: Large‐Scale Manufacture of Peptide Therapeutics by Chemical Synthesis

B. Bray, 2004 .

Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

J. Freyssinet, D. Lane, B. Bray, 1989, The Biochemical journal.

Convergent synthesis of a helical, prehairpin HR1 trimer from HIV gp41

T. Matthews, J. J. Dwyer, S. Schneider, 2010, Journal of peptide science : an official publication of the European Peptide Society.

Development of HIV fusion inhibitors

S. Schneider, B. Bray, L. Stoltenberg, 2005, Journal of peptide science : an official publication of the European Peptide Society.

Lithiated Azafulvenes by Halogen/Metal Interchange of Brominated 6‐(Diisopropylamino)‐1‐azafulvene Derivatives. Novel synthesis of 5‐mono‐ and 4,5‐disubstituted 1H‐pyrrole‐2‐carbaldehydes

B. Bray, J. Muchowski, P. Hess, 1988 .

N-(Triisopropylsilyl)pyrrole. A progenitor "par excellence" of 3-substituted pyrroles

R. Naef, D. R. Artis, B. Bray, 1990 .

Large-scale manufacture of peptide therapeutics by chemical synthesis

B. Bray, 2003, Nature Reviews Drug Discovery.

Heterobiaryl human immunodeficiency virus entry inhibitors.

D. Bolognesi, S. Fisher, M. Greenberg, 2009, Journal of medicinal chemistry.

Improved procedures for the preparation of (+) - (1R, 2S, 4R)-4-amino-2-hydroxy-1-hydroxymethyl cyclopentane

B. Bray, M. Schilling, S. Dolan, 1995 .

Synthesis of (.+-.)-catharanthine, (+)-anhydrovinblastine, and (-)-anhydrovincovaline

B. Bray, R. Lawrence, S. Raucher, 1987 .

Total synthesis of (.+-.)-catharanthine

B. Bray, S. Raucher, 1985 .

Burkholdines from Burkholderia ambifaria: antifungal agents and possible virulence factors.

E. Schmidt, Zhenjian Lin, James E. Cox, 2012, Journal of natural products.

Synthesis of acylpyrroles via .alpha.-(dimethylamino)-.alpha.-pyrrolylacetonitriles

B. Bray, J. Muchowski, 1988 .

The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers.

C. Forbes, G. Houin, M. Mclaren, 1991, British journal of clinical pharmacology.

Burkholdines 1097 and 1229, potent antifungal peptides from Burkholderia ambifaria 2.2N.

S. Khalifa, E. Schmidt, Diaa T. A. Youssef, 2010, Organic letters.

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects

Joo-Youn Cho, K. Yu, S. Schneider, 2014, Drug design, development and therapy.

Design and Synthesis of Human Immunodeficiency Virus Entry Inhibitors: Sulfonamide as an Isostere for the α-Ketoamide Group

Rongshi Li, D. Bolognesi, S. Fisher, 2007 .

Second virial coefficient determination of a therapeutic peptide by self‐interaction chromatography

Robert W. Payne, C. Henry, M. Manning, 2006, Biopolymers.

Thepharmacokinetics ofdermatan sulphate MF701inhealthy humanvolunteers

C. Forbes, G. Houin, M. Mclaren, 1991 .

Process Development of TRI-999, a Fatty-Acid-Modified HIV Fusion Inhibitory Peptide

S. Schneider, B. Bray, S. Wring, 2008 .